75
Participants
Start Date
March 22, 2022
Primary Completion Date
May 2, 2025
Study Completion Date
May 2, 2025
Atogepant
Oral Tablet
Albany Medical College /ID# 242757, Albany
Dent Neurologic Institute - Amherst /ID# 241776, Amherst
Preferred Primary Care Physicians - Jacob Murphy /ID# 241798, Uniontown
Inova Health System /ID# 252242, Falls Church
Puget Sound Neurology /ID# 241787, Tacoma
West Virginia Univ School Med /ID# 252869, Morgantown
Headache Wellness Center /ID# 241791, Greensboro
University of Miami /ID# 252230, Miami
Nashville Neuroscience Group /ID# 243592, Nashville
Arkansas Clinical Research /ID# 241789, Little Rock
Texas Neurology /ID# 241795, Dallas
Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 241812, Phoenix
Neurological Research Institute /ID# 242688, Santa Monica
Hope Clinical Research /ID# 241772, Canoga Park
Neurology and Neurodiagnostics of Alabama /ID# 242538, Hoover
Profound Research LLC /ID# 244084, Carlsbad
Neuro Pain Medical Center /ID# 241992, Fresno
Neurology Offices of South Florida, PLLC /ID# 242693, Boca Raton
Coastal Clinical Research Specialists /ID# 247992, Jacksonville Beach
First Physicians Group - Waldemere /ID# 242861, Sarasota
Kansas Institute of Research /ID# 241796, Overland Park
Ochsner Clinic Foundation /ID# 241803, Covington
Beth Israel Deaconess Medical Center /ID# 241800, Boston
Michigan Headache & Neurological Institute (MHNI) /ID# 241784, Ann Arbor
Minneapolis Clinic of Neurology - Burnsville /ID# 241994, Burnsville
Jefferson Hospital for Neuroscience /ID# 243712, Philadelphia
Chattanooga Medical Research /ID# 253295, Chattanooga
Integrated Neurology Services - Falls Church /ID# 244747, Falls Church
Frontier Clinical Research - Kingwood /ID# 242928, Kingwood
Lead Sponsor
AbbVie
INDUSTRY